$Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL$

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

<p>CD19-CAR T cells in CSF</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Ibrahim Aldoss (15055961) (author)
Kolejni autorzy:	Samer K. Khaled (15055964) (author), Xiuli Wang (15055967) (author), Joycelynne Palmer (15055970) (author), Yan Wang (15055973) (author), Jamie R. Wagner (15055976) (author), Mary C. Clark (15055979) (author), Jennifer Simpson (15055982) (author), Jinny Paul (15055985) (author), Vibhuti Vyas (15055988) (author), Sheng-Hsuan Chien (15055991) (author), Anthony Stein (15055994) (author), Vinod Pullarkat (15047900) (author), Amandeep Salhotra (15055997) (author), Monzr M. Al Malki (15056000) (author), Ahmed Aribi (15056003) (author), Karamjeet Sandhu (15056006) (author), Sandra H. Thomas (15056009) (author), Lihua E. Budde (15056012) (author), Guido Marcucci (11252666) (author), Christine E. Brown (15056015) (author), Stephen J. Forman (15056018) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Hematological Cancers Leukemias Immunotherapy Cellular immunotherapy Engineered/CAR T cells
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Wydane: (2025)

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Wydane: (2025)

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Wydane: (2025)

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Wydane: (2025)

Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Wydane: (2025)

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Wydane: (2025)

Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Wydane: (2025)

Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
od: Julio C. Chavez (15181310)
Wydane: (2025)

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
od: Julio C. Chavez (15181310)
Wydane: (2025)

Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
od: Julio C. Chavez (15181310)
Wydane: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Wydane: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Wydane: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Wydane: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Wydane: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Wydane: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Wydane: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Wydane: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Wydane: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Wydane: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Wydane: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
od: Giuseppe Basile (15051269)
Wydane: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
od: Roger Li (17078665)
Wydane: (2025)

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
od: Samuel Rosner (15054884)
Wydane: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Wydane: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Wydane: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Wydane: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Wydane: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
od: Dwight H. Owen (15034782)
Wydane: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
od: Ruiyun Zhang (17142498)
Wydane: (2025)

Supplementary Table S1-19 from Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations
od: Yuxi Liu (15293121)
Wydane: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
od: Amir T. Fathi (15313195)
Wydane: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
od: Amir T. Fathi (15313195)
Wydane: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
od: Qingsheng Xu (17078830)
Wydane: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
od: Qingsheng Xu (17078830)
Wydane: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
od: Nam Q. Bui (14958210)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lt98lun07gvcg724rondkc5esr